BioSpace News Archive

Aptose Biosciences Inc., a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the second quarter ended September 30, 2019 on Tuesday, November 5, 2019 after the close of the market.

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress..

Neovasc, Inc. announced that the Neovasc Reducer™ was featured in multiple presentations during the symposium “A Proven Evidence-based therapy when Angina Persists”, held this month at the National Congress of the Italian Society of Interventional Cardiology in Milan, Italy.

Eton Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Anixa Biosciences, Inc. announced the acceptance of an abstract at the 34th Annual Meeting of the Society for Immunotherapy of Cancer A poster presentation will include data from ongoing studies utilizing Cchek™, the company’s artificial intelligence driven cancer detection technology.

The Industry Relations Committee represents all aspects of Biofabrication including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization

MYOS CEO Joseph Mannello to Speak at the ‘Innovation Showcase’ on November 8 at 12:30pm ET

Excellent Safety Profile and Improvements in Clinically Relevant Secondary Endpoints (Endoscopy and Histology) Support Further Development by a Partner

Webcast scheduled for Wednesday, November 6th at 11:30 a.m. Eastern Time

First Pivotal Study to Investigate Permanent Vascular Implant as a Treatment for Post-Angioplasty Dissections in Arteries Below the Knee (BTK)